R05CB13 • dornase alfa • Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics
Dornaza alfa is a medication used for the treatment of cystic fibrosis. It is a recombinant enzyme that breaks down DNA in the thick mucus accumulated in the lungs, facilitating its clearance and improving respiratory function.
The medication is administered via inhalation, usually once daily, using a nebulizer. It is effective in reducing the frequency of respiratory infections and alleviating respiratory symptoms.
Side effects may include sore throat, hoarseness, skin rash, and, in rare cases, severe allergic reactions. Regular monitoring is essential to assess treatment effectiveness.
Consult your doctor to discuss the benefits and risks of treatment with Dornaza alfa. Follow the usage instructions to ensure therapy effectiveness.
Substance: dornase alfa
Date of last drug list: 01-07-2016
Commercial code: W51323001
Concentration: 1mg / ml
Pharmaceutical form: inhalation solution
Quantity: 6
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).